Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

NCT06874946 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
T - Cell Lymphoma
PTCL

Interventions

BIOLOGICAL: CD5-targeted CAR-T cells

Sponsor

Peking University People's Hospital

Collaborators

[object Object]